2024
Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, Harris T, Hunt B, Fass R, Katz P. Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. Clinical Gastroenterology And Hepatology 2024, 22: 2211-2220.e10. PMID: 38750866, DOI: 10.1016/j.cgh.2024.05.004.Peer-Reviewed Original ResearchNon-erosive reflux diseaseHeartburn-free daysErosive esophagitisReflux diseaseRandomized trialsActive-treatment extensionRandomized to placeboPotassium-competitive acid blockerPlacebo-controlled periodDays of therapyPercentage of subjectsPrimary endpointPercentage of daysHeartburn symptomsPlaceboVonoprazanAcid blockerNighttime heartburnDay 1Randomized subjectsDocumented efficacyStudy armsDay 2Adult subjectsExtension period
2022
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology 2022, 164: 61-71. PMID: 36228734, DOI: 10.1053/j.gastro.2022.09.041.Peer-Reviewed Original ResearchConceptsMaintenance of healingProton pump inhibitorsErosive esophagitisSecondary analysisD esophagitisPrimary analysisEnd pointPotassium-competitive acid blocker vonoprazanHeartburn-free daysSevere erosive esophagitisMainstay of treatmentPrimary end pointSecondary end pointsPotent acid inhibitionPPI lansoprazolePump inhibitorsEsophagitisNoninferiority comparisonVonoprazanWeek 2Healing phaseAbstractTextPatientsLansoprazoleSuperiority analysisPharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, Howden CW. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. The American Journal Of Gastroenterology 2022, 117: 1158-1161. PMID: 35294415, DOI: 10.14309/ajg.0000000000001735.Peer-Reviewed Original Research